Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

MeDiApp-PCOS: A Mobile Mediterranean Diet App for Women With Polycystic Ovary Syndrome (MeDiApp-PCOS)

31 mai 2026 mis à jour par: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Randomized Controlled Trial of a Mobile Application With Personalized Mediterranean Diet-Based Recommendations in Women With Polycystic Ovary Syndrome

This randomized clinical trial will test whether a mobile application with personalized Mediterranean diet-based recommendations can improve health outcomes in women with polycystic ovary syndrome compared with standard lifestyle advice.

Participants will be assigned to either the mobile application group or the standard lifestyle advice group.

The primary outcomes are change in LDL cholesterol and change in body mass index after 3 months.

Secondary outcomes include changes in metabolic and hormonal measures, quality of life, treatment adherence, and ovulatory function assessed through 6 months.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Female participants aged 18 to 45 years.
  • Diagnosis of polycystic ovary syndrome (PCOS) with an anovulatory phenotype according to the Rotterdam criteria (2003).

  • Oligo-ovulation or anovulation, defined as menstrual cycle length greater than 35 days or fewer than 8 menstrual periods per year, together with at least one of the following:

    • Clinical and/or biochemical hyperandrogenism.
    • Polycystic ovarian morphology on ultrasound, defined as at least 20 follicles measuring 2 to 9 mm in either ovary and/or ovarian volume of at least 10 cm3.
  • Possession of a smartphone compatible with the study application (Android or iOS).
  • Ability and willingness to use the mobile application and comply with study procedures.
  • Provision of written informed consent before any study-specific procedures are performed.

Exclusion Criteria:

  • Pregnancy or breastfeeding at the time of enrollment.
  • Planning pregnancy during the study period.
  • Type 1 or type 2 diabetes mellitus.
  • Other endocrine disorders that may affect reproductive or metabolic function, including Cushing syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, or uncontrolled thyroid disease.
  • Severe liver disease, including cirrhosis or liver failure.
  • Severe renal impairment, defined as estimated glomerular filtration rate less than 30 mL/min/1.73 m2.
  • Severe cardiovascular disease, including unstable angina, myocardial infarction within the previous 6 months, or stroke within the previous 6 months.
  • Use within the previous 3 months of medications that may affect body weight, carbohydrate metabolism, androgen status, or reproductive function, including metformin, oral contraceptives, antiandrogens, gonadotropin-releasing hormone agonists or antagonists, clomiphene citrate, glucocorticoids, thiazolidinediones, or weight-loss drugs.
  • Current or past eating disorders, including anorexia nervosa, bulimia nervosa, or binge eating disorder.
  • Mental disorders or cognitive conditions that, in the opinion of the investigator, would preclude safe participation or compliance with study procedures.
  • Participation in another clinical trial within the previous 3 months.
  • Refusal or inability to provide written informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Mobile Application With Personalized Mediterranean Diet-Based Recommendations

Participants randomized to this arm will receive access to a mobile application specifically developed for women with polycystic ovary syndrome.

The application provides personalized dietary recommendations based on the Mediterranean diet, a system for tracking food intake and physical activity, automated feedback and motivational messages, weekly progress reports, and educational materials on PCOS and healthy lifestyle.

Participants will be instructed to use the application daily for 6 months, including completion of nutrition and activity diaries and review of recommendations and feedback.
Comportemental: Mobile Application-Based Personalized Mediterranean Diet and Lifestyle Intervention

The intervention consists of a mobile application providing personalized Mediterranean diet-based nutrition plans, a food database with nutritional information, automatic calculation of caloric intake and macronutrient composition, monitoring of adherence to the Mediterranean diet, physical activity recommendations (including minimum weekly minutes of moderate aerobic activity and strength training), an activity diary with step tracking, automated feedback and motivational messages, weekly progress reports, push notifications with reminders, and educational materials on PCOS and healthy lifestyle.

Participants are instructed to use the application daily for 6 months, to enter food intake and physical activity, and to review personalized feedback. The intervention aims to optimize dietary habits, increase physical activity, improve metabolic parameters, and support restoration of ovulatory function in women with PCOS.
Comparateur actif: Standard Lifestyle Advice

Participants randomized to this arm will receive standard written recommendations for lifestyle modification in polycystic ovary syndrome, including principles of the Mediterranean diet, recommended foods and example menus, and physical activity recommendations.

They will receive a one-time consultation with a dietitian at baseline with explanation of the recommendations and will be advised to keep a paper diary of nutrition and physical activity during the follow-up period.

No access to the mobile application will be provided in this arm.
Comportemental: Standard Lifestyle Advice for PCOS

Standard care consisting of written lifestyle recommendations for women with polycystic ovary syndrome.

This includes printed materials describing the Mediterranean diet (principles, recommended and discouraged foods, example menus), physical activity recommendations, and general educational information on PCOS and the importance of lifestyle changes.

Participants will receive a one-time dietitian consultation at baseline to review the recommendations and will be advised to keep a paper diary of nutrition and physical activity throughout the follow-up period. No digital application or additional feedback system will be provided.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in LDL cholesterol from baseline to 3 months
Délai: Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Serum low-density lipoprotein (LDL) cholesterol concentration measured in mmol/L after an overnight fast
Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Change in body mass index (BMI) from baseline to 3 months
Délai: Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Body mass index calculated as weight (kg) divided by height (m²)
Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in fasting insulin and HOMA-IR from baseline to 3 months
Délai: Baseline (Visit 1) and Month 3 (Visit 2)

Fasting serum insulin (μIU/mL) and insulin resistance assessed by HOMA-IR index, calculated as (fasting glucose × fasting insulin) / 22.5.

Changes will be calculated as values at 3 months (Visit 2) minus baseline values (Visit 1)
Baseline (Visit 1) and Month 3 (Visit 2)
Change in triglycerides and HDL cholesterol from baseline to 3 months
Délai: Baseline (Visit 1) and Month 3 (Visit 2)

Fasting serum triglycerides and high-density lipoprotein (HDL) cholesterol measured using standard enzymatic methods.

Changes will be calculated as values at 3 months (Visit 2) minus baseline (Visit 1).
Baseline (Visit 1) and Month 3 (Visit 2)
Proportion of participants achieving at least 5% weight loss at 3 months
Délai: Baseline (Visit 1) and Month 3 (Visit 2)

Percentage of participants with a reduction in body weight of ≥5% from baseline to 3 months.

Weight is measured in light clothing without shoes. Proportion will be compared between groups using chi-square or Fisher's exact test.
Baseline (Visit 1) and Month 3 (Visit 2)
Restoration of regular menstrual cycles during 3-6 months
Délai: From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)

Proportion of participants who achieve regular menstrual cycles, defined as cycle length 21-35 days, during the period between Month 3 and Month 6 of follow-up.

Information will be collected from menstrual calendars reviewed at Visit 3.
From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)
Frequency of ovulatory cycles during 3-6 months
Délai: From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)

Number and proportion of ovulatory cycles per participant during the period from Month 3 to Month 6.

Ovulation will be confirmed by serum progesterone >5 ng/mL on cycle days 21-23 and/or by ultrasound follicle monitoring when indicated.
From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)
Adherence to mobile application use at 3 months (main group only)
Délai: From Day 0 to Month 3
Adherence will be assessed as the percentage of days with completed nutrition diaries and the mean Mediterranean diet adherence score calculated automatically by the mobile application over the 3 month period.
From Day 0 to Month 3
Serum total testosterone, free androgen index (calculated), androstenedione and sex hormone-binding globulin (SHBG) measured by immunochemiluminescence assays. Changes will be calculated as 3 month values minus baseline values.
Délai: Baseline (Visit 1) and Month 3 (Visit 2)

Serum total testosterone, free androgen index (calculated), androstenedione and sex hormone-binding globulin (SHBG) measured by immunochemiluminescence assays.

Changes will be calculated as 3 month values minus baseline values.
Baseline (Visit 1) and Month 3 (Visit 2)
Change in inflammatory markers: IL-5, Il-22, IL-1 RA,MCP-1, CCL-7 from baseline to 3 months
Délai: Baseline (Visit 1) and Month 3 (Visit 2)
Inflammatory markers measured using standard assays. Changes are defined as 3 month values minus baseline values.
Baseline (Visit 1) and Month 3 (Visit 2)
Change in Mediterranean diet adherence score (15-Items Pyramid based Mediterranean Diet Score (PyrMDS)) from baseline to 3 months
Délai: Baseline (Visit 1) and Month 3 (Visit 2)

Final score: 0-15

  • 0-5 points - Low adherence to the Mediterranean diet
  • 6-9 points - Moderate adherence to the Mediterranean diet
  • 10-12 points - Good adherence to the Mediterranean diet
  • 13-15 points - High adherence to the Mediterranean diet
Baseline (Visit 1) and Month 3 (Visit 2)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

13 mai 2026

Achèvement primaire (Estimé)

30 décembre 2028

Achèvement de l'étude (Estimé)

30 juin 2029

Dates d'inscription aux études

Première soumission

13 mai 2026

Première soumission répondant aux critères de contrôle qualité

13 mai 2026

Première publication (Réel)

20 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

31 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 125042105343-8

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner